a success story: idh inhibitors for aml
Published 5 years ago • 81 plays • Length 2:13Download video MP4
Download video MP3
Similar videos
-
1:25
idh inhibitors for aml: highlights from ash 2018
-
1:37
long-term follow-up from a phase ii trial of olutasidenib in idh1-mutated aml
-
1:23
decitabine, venetoclax, and idh inhibitor in idh-mutated aml
-
0:54
idh inhibitors and the evolving aml treatment paradigm
-
0:59
idh inhibitors in aml
-
2:22
session highlights: idh inhibitors, salvage regimens, and other novel developments in aml
-
6:11
first-in-human study of the menin-kmt2a inhibitor jnj-75276617 in r/r acute leukemias
-
28:19
diagnosis: morphology, flow cytometry, cytogenetics, molecular testing, and risk-stratification
-
35:20
founder stories: winston yan, co-founder of arbor biotechnologies & crispr discovery
-
2:41
advancements in aml: an update from ash 2023
-
1:51
idh1/2 inhibitors for upfront aml therapy and transfusion independence
-
2:44
the global expansion of modern aml therapy through the international consortium on acute leukemia
-
1:55
diagnosing and treating aml: the role of mutational profiling
-
0:52
rilzabrutinib: a novel promising btk inhibitor being explored in itp
-
6:31
a meta-analysis assessing the safety of cytoreductive therapies in younger patients with pv
-
0:56
promising combinations being explored for idh1 & idh2-mutated aml
-
4:09
key considerations for community physicians in the management of secondary aml
-
1:03
an insight into the sequencing of immunotherapies in adults with all
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
2:51
aml: mutant idh1 inhibitor hms-101
-
1:27
incorporating new technologies into the real-life classification of aml to guide treatment decisions